Get all premium features to the best stock analysis tool

IRADIMED CORPORATION to Participate at the 38th Annual Roth Conference

ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) today announced that it will participate in the 38 th Annual Roth Conference.

IRADIMED CORPORATION Reports Record Fourth Quarter and Full Year of 2025 Financial Results and Increases its Regular Quarterly Cash Dividend to $0.20 Per Share from $0.17 Per Share

ORLANDO, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company” or “Iradimed”) (NASDAQ: IRMD) announced today its financial results for the quarter and year ended December 31, 2025. The Company is a leader in developing innovative magnetic resonance imaging (“MRI”) compatible medical devices and products. The Company is a provider of (i) non-magnetic intravenous (“IV”) infusion pump systems and (ii) non-magnetic patient vital signs monitoring systems that are each designed for use during MRI procedures.

IRADIMED Announces Special Cash Dividend of $0.50 Per Share

ORLANDO, Fla., Dec. 08, 2025 (GLOBE NEWSWIRE) -- iRadimed Corporation (the “Company”) (NASDAQ: IRMD), announced that its Board of Directors (the “Board”) approved a special cash dividend of $0.50 per share of the Company's outstanding common stock. This special cash dividend is payable on December 30, 2025, to stockholders of record at the close of business on December 17, 2025. The Company is a leader in developing innovative magnetic resonance imaging (“MRI”) compatible medical devices and products. The Company produces the only known non-magnetic intravenous (“IV”) infusion pump system and a non-magnetic patient vital signs monitoring system designed for use during MRI procedures.

IRADIMED CORPORATION Named to TIME's List of America's Growth Leaders for 2026

Recognized for Exceptional Revenue Growth, Financial Stability, and Stock Performance Recognized for Exceptional Revenue Growth, Financial Stability, and Stock Performance